Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 8 5 W ELECTROLYTES versus AMINOSYN II 8 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 8 5 W ELECTROLYTES versus AMINOSYN II 8 5 W ELECTROLYTES.
AMINOSYN 8.5% W/ELECTROLYTES vs AMINOSYN II 8.5% W/ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 8.5% with Electrolytes is a crystalline amino acid solution used for parenteral nutrition. It provides essential and non-essential amino acids necessary for protein synthesis, tissue repair, and maintenance of nitrogen balance. Electrolytes are included to maintain acid-base balance and normal cellular function.
Amino acids serve as substrates for protein synthesis and provide nitrogen for metabolic processes. Electrolytes maintain acid-base balance and osmotic pressure.
Intravenous infusion: 500 mL to 1000 mL of 8.5% solution (42.5-85 g amino acids) once daily, infused at a rate not exceeding 100 mL/hour.
1 to 1.5 g amino acids/kg/day intravenously, typically infused over 12-24 hours.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for essential amino acids and 0.5-2 hours for non-essential amino acids, reflecting rapid distribution and metabolism in healthy adults. In renal or hepatic impairment, half-life may be prolonged.
Variable; amino acids typically have half-lives of minutes to hours; free amino acids in plasma have t1/2 of 10-30 minutes for most
Amino acids are primarily eliminated via metabolism (deamination, transamination) and incorporation into proteins. Unmetabolized amino acids are excreted renally (approximately 5-10% of administered dose, depending on renal function and infusion rate). Fecal and biliary excretion are negligible (<1%).
Renal >90% (as amino acids and metabolites); fecal <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution